41st Annual J.P. Morgan Healthcare Conference Presentation

January 10, 2023

Forward-Looking Statements

Except for the historical information discussed today and contained herein, the matters discussed today and set forth in this presentation are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding consistent future revenue growth, projected revenues in 2026, our ability to advance our pre-clinical product candidates; our ability to launch products and product candidates as planned in 2023 and afterwards; our ability to successfully close on the transaction to acquire commercial rights to a biosimilar candidate to Eylea® in Q1 2023 or at all; our projections for the size and growth of the anti-VEGF market and other markets and our ability to gain market share or revenue growth in any of the markets for our other products and product candidates; our projections about commercial synergies that may exist between our products and product candidates; our future ability to scale our ophthalmology franchise; our projections for sales of CIMERLI™ in the future; our ability to expand payer coverage; our projections for market size for UDENYCA® OBI; our ability to gain approval for our product candidates in the future with the FDA; our ability to establish our products and product candidates as the standard of care for first-line treatment; expectations about the size of the market for YUSIMRY™ and our ability to compete to gain share in a large market; and our expectations about our capacity to supply the adalimumab market. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus' actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties caused by our transition from a biosimilar focused company to an innovative immuno-oncology franchise funded by sales from FDA-approved therapeutics; the risks and uncertainties of the COVID-19 pandemic; the risks and uncertainties inherent with clinical research and commercialization; the risks and uncertainties of the clinical development and regulatory approval process, including (but not limited to) the timing of Coherus' regulatory filings and the ability of the FDA to complete required inspections outside of the U.S.; the risk that Coherus is unable to complete commercial transactions, such as the transaction to acquire commercial rights to a biosimilar candidate to Eylea®; risks and uncertainties in executing collaboration agreements and other joint ventures, including particular risks of working with international partners; and the risks and uncertainties of litigation. All forward-looking statements contained in this press release speak only as of the date on which they were made. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus' business in general, see Coherus' Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed with the Securities and Exchange Commission on November 8, 2022, including the section therein captioned "Risk Factors," and in other documents Coherus files with the Securities and Exchange Commission. UDENYCA®, YUSIMRY™ and CIMERLI™, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners, unless otherwise noted. Trademarks and trade names of other companies appearing in this presentation are, to the knowledge of Coherus, the property of their respective owners.

Agenda

- Company Strategy and Summary
- Ophthalmology Franchise
- Oncology Franchise
- YUSIMRY™ – Inflammatory Disease
- Summary and Investment Rationale

Strong Strategic Progress

Multiple Near-Term Product Launches and Innovative I-O Pipeline Provide Sustained Value Creation for Investors

Product Launch Plan

CIMERLI™ (ranibizumab-eqrn) injection	Q4 '22
TORIPALIMAB toripalimab-tpzi Injection 240 mg	1H '23
YUSIMRY™ (adalimumab-aqvh) Injection	Q3 '23
UDENYCA® pegfilgrastim-cbqv	2023
Eylea® Biosimilar* (aflibercept-xxxx)	2025

Revenue Growth Supports Innovative Immuno-Oncology Pipeline

- **Consecutive product launches and sustained revenue growth through the end of the decade**
  - Biosimilars
  - Novel and Innovative Oncology
  - Projected 2026 revenues of $1.2B or greater
- **Toripalimab provides the foundation for I-O combinations**
  - CHS-006, anti-TIGIT antibody Phase 1/2 Study active in US, Coherus sponsored
  - CHS-1000, ILT4 antibody, 2023 IND
  - Additional proprietary novel I-O candidates

*Assumes closing on definitive agreements for the exclusive commercialization rights to a biosimilar candidate to Eylea in Q1 2023.

Agenda

- Company Strategy and Summary
- **Ophthalmology Franchise**
- Oncology Franchise
- YUSIMRY™ – Inflammatory Disease
- Summary and Investment Rationale

Eylea® Biosimilar Expands Access to the US Ophthalmology Anti-VEGF Market - a Significant Commercial Opportunity

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

Additional Growth Driver projected to significantly increase Mid-to-Long-Term Revenue Potential

REDWOOD CITY, Calif., January 9, 2023 (GLOBE NEWSWIRE)— Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that it has executed a binding term sheet with Klinge Biopharma GmbH (Klinge Biopharma) for the exclusive commercialization rights to FYB203, a biosimilar candidate to Eylea® (aflibercept), in the United States. The parties expect to complete the transaction in Q1 2023, and Coherus plans to file a Biologics License Application with the U.S. Food and Drug Administration later this year. Coherus intends to launch the product at Eylea® biosimilar market formation, currently expected to be in 2025 if approved.

Eylea® and Lucentis® Dominate the Retina Tx Market by Dollar Volume



Retinal Disease Treatment 2021 Market Share ($7.4B Revenue)

Source: **1.** EvaluatePharma Retinal Disease Market Overview; **2.** DataMonitor wAMD Market Landscape.

Ophthalmology Anti-VEGF Market has >$12B Potential with Significant Opportunity for Expansion



Expanding across the continuum of care maximizes opportunities for CIMERLI™ and Eylea® biosimilar to establish market formation leadership

- Adding Eylea® biosimilar* significantly expands our addressable market
  - Meaningfully leverages our successful investment in building our commercial ophthalmology franchise
- CIMERLI™ provides ophthalmologists with an FDA-approved alternative to off-label Avastin®
- Reformulated Avastin comprises ~40% anti-VEGF unit market share

*Assumes closing on definitive agreements for the exclusive commercialization rights to a biosimilar candidate to Eylea in Q1 2023.

CIMERLI™ (ranibizumab-eqrn) injection

Sources: Lucentis: IQVIA DDDMD, latest 3 months (week ending 9/30/22 – 12/23/22); Eylea: quarterly units derived from Regeneron 1Q22 Financial report and WAC price; Avastin: estimated ophthalmology units based on CMS 2019 data, Compile medical claims (April 2021 – March 2022), and IQVIA DDDMD (53 weeks ending 7/29/2022)

Coherus BIOSCIENCES

An Eylea® Biosimilar* is Commercially Synergistic with CIMERLI™ and has a High ROI Potential

- During the CIMERLI™ launch, healthcare provider feedback indicated robust pent-up demand for an Eylea® biosimilar
- Significant revenue opportunity 2025 - 2030
- Substantial commercial synergies minimize incremental investment
  - Experienced retina commercial team in place with established customer relationships
  - Leverages demonstrated “Buy & Bill” market expertise in Oncology, and now Ophthalmology
- Coherus US Ophthalmology Franchise has the bandwidth to accommodate future additional products based on common call points

*Assumes closing on definitive agreements for the exclusive commercialization rights to a biosimilar candidate to Eylea in Q1 2023.

Coherus BIOSCIENCES

Interchangeability plus Exclusivity Defines CIMERLI™ as the Market Formation Leader

Strengths to Leverage	Implications	Coherus Advantage
Large Anti-VEGF Market	Access to the $7.4B Retina Market	Lucentis $1.2B & Avastin (40% of units)
Full Label + Interchangeability	Transition Stable Patients	Fast Market Conversion
Market Concentration	80% of Lucentis in 450 Accounts	Focused Sales Force Effort
Experienced Sales Force	Established Relationships	Access to Deliver CIMERLI Value Proposition

Expecting to Deliver Over $100M Sales in 2023

Source: Company projections

CIMERLI™ Launch Progress

Strong Commercial Execution Consistent with UDENYCA® Launch

- **>3,200** sales calls delivered since launch[1]
- **93** Key accounts have purchased[2] CIMERLI™
- **Q-Code Expected 4/1** to accelerate market conversion
- **Strong, Expanding Payer Coverage[3]**
  - 100% Medicare Fee for Service
  - 59% Commercial Lives Covered
  - 46% Medicare Advantage Lives

CMS CENTERS FOR MEDICARE & MEDICAID SERVICES

Cigna. EXPRESS SCRIPTS

Anthem BlueCross BlueShield

PRIME THERAPEUTICS

Humana.

Market Share[4]



CIMERLI™ Tracking to the UDENYCA® Success Story

CIMERLI™ (ranibizumab-eqrn) injection

Sources: **1.** Coherus Internal CRM data – launch 10/3/22; **2.** 3PL 867 data (ending 12/23/2022); **3.** Based on confirmed formulary access as a % of lives as of Dec 31, 2022; **4.** IQVIA WSP data

Coherus BIOSCIENCES

Agenda

- Company Strategy and Summary
- Ophthalmology Franchise
- **Oncology Franchise**
- YUSIMRY – Inflammatory Disease
- Summary and Investment Rationale

UDENYCA® OBI: Supplemental BLA Filed in 2022
Expected Launch in 2023

Strengths to Leverage	Implications	Coherus Advantage
On Body Injector Format	On Body Segment ~ 45% of Market	Compete Directly for Onpro Share
Existing Market Access Positions	OBI Added to Established Agreements	Enable Quick Uptake for UDENYCA® OBI
Experienced Sales Force	Deep Customer Relationships	Ability to Drive Sales and Conversions
Select Points of Device Differentiation	Compete on Factors Beyond Price	Anticipate Offering a Compelling Value Proposition

On-Body Injector Will Enable UDENYCA® to Compete for Market Share Leadership

Source: Company projections

Coherus BIOSCIENCES

UDENYCA® On-Body Injector

Catalyst for Second Wave of Pegfilgrastim Market Share Growth

Q3 2022 Pegfilgrastim Market Share[1]



UNDENYCA OBI Arms Coherus to Compete for an Additional 600k Annual Onpro Units


Journal of Clinical Oncology®
An American Society of Clinical Oncology Journal

Meeting Abstract | 2022 ASCO Annual Meeting I

HEALTH SERVICES RESEARCH AND QUALITY IMPROVEMENT

A randomized, open-label, crossover study assessing the pharmacokinetic and pharmacodynamic bioequivalence of pegfilgrastim-cbqv via on-body injector vs prefilled syringe.

e18637

Background: Pegfilgrastim-cbqv, a pegfilgrastim biosimilar, is administered 24-72 h after myelosuppressive chemotherapy to prevent febrile neutropenia. Pegfilgrastim delivery via an on-body injector (OBI) applied on the day of chemotherapy eliminates the need for a second healthcare visit. This study evaluated the pharmacokinetic (PK), pharmacodynamic (PD) bioequivalence (BE), and the safety of pegfilgrastim-cbqv administered via OBI vs prefilled syringe. **Methods:** In this open-label, 2-period crossover study, healthy adult

Differentiated Device Features

Established PK and PD Bioequivalence[3]

UDENYCA® pegfilgrastim-cbqv

Source:1. IQVIA DDD data Q3 2022; 2. Weekly NSP data per 12/29 Coherus Demand Tracker report.; 3. Tang, et al, ASCO Abstract# e18637 June 2022; Neulasta® and Onpro® are registered trademarks of Amgen, Inc.

Coherus BIOSCIENCES

Toripalimab Provides the Foundation for a Broad Immuno-Oncology Portfolio as well as Future Partnering Opportunities

Essential Foundation of an I-O Franchise with Development from Preclinical to BLA Review

- Enables rapid and cost-effective PD-1 combination development
- Commercial flexibility



Differentiated Profile

- Optimized during discovery (unique epitope)
- Intriguing clinical data (PFS improvement in PD-L1 low across ESCC, NPC, and NSCLC)



Platform for Combination Development

- Establish toripalimab as SOC in NPC upon approval anticipated in 2023
- Pursue other registration opportunities
- TIGIT, ILT4, other combinations



In I-O, there is a bifurcation between companies *who have a PD-1* and those *who do not*

Access to PD-1 via license is required for new PD-1 combinations

Combination therapy provides best opportunity to extend patient survival

Coherus BIOSCIENCES

Toripalimab has Significantly Extended Patient Survival in Nasopharyngeal Carcinoma

External Scientific Validation

2021 ASCO ANNUAL MEETING

Featured at plenary session

Progression-Free Survival

by BIRC per RECIST v1.1



Overall Survival



Median PFS

- 11.7 months – Toripalimab + chemo vs 8.0 months chemo alone

1-year PFS

- 49% Toripalimab + chemo vs. 28% chemo alone

TORIPALIMAB
toripalimab-xxxx Injection 240 mg

Source: Mai, HQ., Chen, QY., Chen, D. et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. *Nat Med* 27, 1536–1543 (2021). https://doi.org/10.1038/s41591-021-01444-0

Coherus BIOSCIENCES

Nasopharyngeal Carcinoma is a Rare Cancer with High Unmet Need and No FDA-Approved Immunotherapy Products



Toripalimab + Chemo has the Potential to Become the New Standard of Care for First-Line Treatment

High Burden of Disease

- 0.5-2 cases per 100,000 annual incidence in the U.S.
- Median average 5-year survival rate of 20% in R/M NPC

Current Treatment Landscape

- No FDA-approved I-O treatment
- Chemotherapy is SOC

Market Potential

- $100M - $200M Opportunity (across 1L and 2L+)

TORIPALIMAB
toripalimab-xxxx Injection 240 mg

Sources: **1.** DRG and Cancer.net; **2.** Coherus Internal Research; Note: Patient incidence based on internal research & forecast as of 12/03/21

Coherus BIOSCIENCES

High Overlap in Accounts Creates Synergy in Launch Execution

PD-1 and UDENYCA® Account Overlap



Synergy & Focused Execution

- **65% NPC Patients** Come from **UDENYCA® Accounts**
- **640 HCPs Treat 50% of NPC Patients**

UDENYCA® pegfilgrastim-cbqv

Sources: IQVIA Claims data through 3/31/2021, R3Y totals.; PD1 DDD data through 10/31/2020, R12M totals; UDENYCA Xponent and DDD data through 3/31/2021, R12M totals.

Coherus BIOSCIENCES

Unique Epitope and Mechanism of Action:

Toripalimab binds a unique epitope with very high affinity

1 Toripalimab Binds a Unique Epitope on PD-1



2 Toripalimab has Shown to Have High Affinity

Antibody	K_D (nM)	Epitope
Toripalimab	0.3	FG loop
Pembrolizumab	7.0	CD loop
Nivolumab	10.5	N-terminus

- Toripalimab optimized during discovery with potency and unique CDR sequences and epitope

Source: “Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China” Lin et al. Frontiers in Immunology, Volume 12. 2022. https://www.frontiersin.org/article/10.3389/fimmu.2021.730666

Coherus BIOSCIENCES

Toripalimab with Chemotherapy in ESCC Demonstrates Efficacy Independent of PD-L1 Expression

Toripalimab
JUPITER-06[1]
Overall Survival

Pembrolizumab
KEYNOTE-590[2]
Overall Survival



Toripalimab in Combination with Chemotherapy also Demonstrated an Improvement in PFS and OS Over Placebo Across all PD-L1 Expression Levels for NPC[3] and NSCLC[4] Phase 3 Studies

1. Shun Yamamoto, Ken Kato, JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma, Cancer *Cell*, Volume 40, Issue 3, 2022, Pages 238-240, ISSN 1535-6108, https://doi.org/10.1016/j.ccell.2022.02.009; **2.** Pembrolizumab Jong-Mu Sun, Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomized, placebo-controlled phase 3 study. *The Lancet*, Vol 398. August 28, 2021.; **3.** Mai, HQ., Chen, QY., Chen, D. et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. *Nat Med* 27, 1536–1543 (2021); **4.** Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01), *Journal of Clinical Oncology* October 2022, DOI: 10.1200/JCO.22.00727.

Coherus BIOSCIENCES

PD-1 and TIGIT are Two Key Mechanisms for Tumor Immune Evasion

TIGIT and PD-1 are both co-expressed on T-cells

TIGIT and PD-1 are both checkpoint inhibitors on T-cells



TIGIT Combined with Toripalimab May Work Together to Extend Survival



TIGIT is a Rational Combination with Toripalimab

- PD-1 and TIGIT have Cross Talk and Overlapping Mechanisms through Shp2
- TIGIT Plus PD-1 has the Potential to Maximize Anti-Tumor Immunity

TORIPALIMAB
toripalimab-xxxx Injection 240 mg

Source: "Immune Checkpoint Blockade in Cancer Therapy"; Allison, James; Nobel Lecture (December 2018)

Coherus BIOSCIENCES

Toripalimab + TIGIT Phase 1/2 Clinical Study is Active in the US



Primary Objectives

- Safety and tolerability of TIGIT (CHS-006/JS006) in combination with toripalimab and determine the recommended Phase 2 dose

Secondary Objectives

- Efficacy and PK

Milestones & Timing

- Initiated Q4 2022
- FPI expected Q1 2023
- Efficacy data from Junshi studies expected in 2023
- Efficacy data from U.S. study efficacy in 2024

TORIPALIMAB
toripalimab-xxxx Injection 240 mg

Coherus BIOSCIENCES

Increased Understanding of the Immunity Cycle has Resulted in an Increasing Number of Potential Rational Combinations





Coherus BIOSCIENCES

ILT4 is a Key Target for Repolarization of M2 (suppressive) Macrophages to M1 (inflammatory) Macrophages



Coherus BIOSCIENCES

Agenda

- Company Strategy and Summary
- Ophthalmology Franchise
- Oncology Franchise
- **YUSIMRY™ – Inflammatory Disease**
- Summary and Investment Rationale

YUSIMRY™: Primed for Competitive Launch in July

Strengths to Leverage	Implications	Coherus Advantage
Large Addressable Market	$17B Market	Launching at Market Formation
Payer Driven Market	Low Net Price and Supply Guarantees are Top Requirements	YUSIMRY Designed to Address Payer Needs
Experienced Sales Force	Capacity to Supply ~10% of Market in Year 1 with Potential to Scale Up to ~30% Overall Market	Supply Guarantees Expected to Differentiate Coherus from Other Biosimilars



Competitive Pricing and Dedicated Supply Position YUSIMRY as a Formidable Competitor

Source: Company projections

Coherus BIOSCIENCES

Agenda

- Company Strategy and Summary
- Ophthalmology Franchise
- Oncology Franchise
- YUSIMRY™ – Inflammatory Disease
- **Summary and Investment Rationale**

Near-Term Product Launches and Innovative I-O Pipeline Provide Long-Term Growth and Sustained Value Creation

Innovative Immuno-Oncology Pipeline

Candidate	Target	Proposed Indication
TORIPALIMAB*	PD-1	Nasopharyngeal Carcinoma (1L combo with chemo) Nasopharyngeal Carcinoma (2L/3L monotherapy)
CHS-006*	TIGIT	Hepatocellular Carcinoma Non-small Cell Lung Cancer Small Cell Lung Cancer Solid Tumors (All indications in combination with toripalimab)
CHS-1000	ILT4	Solid Tumors (in combination with toripalimab)



Biosimilar Cash Flows Fund the Pipeline

Therapeutic Area	Product / Candidate
Oncology	**UDENYCA®** (pegfilgrastim-cbqv)
Oncology	**UDENYCA® OBI** (pegfilgrastim-cbqv)
Ophthalmology	**CIMERLI™** (ranibizumab-eqrn)
Immunology	**YUSIMRY™** (adalimumab-aqvh)
Ophthalmology	**EYLEA®** Biosimilar** (aflibercept-xxxx)



*In the U.S.

**Assumes closing on definitive agreements for the exclusive commercialization rights to a biosimilar candidate to Eylea in Q1 2023.

Coherus BIOSCIENCES